JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: Hence, this study's objectives were to evaluate the relationships between JAK2 gene expression, total JAK2 protein, phosphorylated JAK2 levels, and CHR, as well as EMR before and after 3 months of imatinib treatment in patients with chronic phase CML.